Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cerebrovascular Circulation
- Sponsor
- Centre Antoine Lacassagne
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- diagnostic performance of the 18F-FDG PET
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Chronic stenosing cerebral vascular pathology (stenosis \> 70% on Doppler examination or angiography).
- •Patient aged over 18 years.
- •Patient who has voluntarily agreed to participate in the study and has signed the written informed consent.
- •Patient affiliated with a social security system.
Exclusion Criteria
- •Patient with stenosis less than 70% on Doppler examination or angiography.
- •Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L).
- •Patient with a contraindication to scintigraphy.
- •Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®).
- •Patient enrolled in another clinical study with a specified exclusion period.
- •Minor patient.
- •Patient unable to give informed consent.
- •Vulnerable individuals
Outcomes
Primary Outcomes
diagnostic performance of the 18F-FDG PET
Time Frame: 12 months
The primary endpoint is the sensitivity of the examination in detecting a decrease in cerebral vascular reserve (CVR). The presence or absence of a decrease in CVR for each patient will be determined by clinical consensus, based in particular on spontaneous follow-up (clinical progression, cerebral ischemic episodes, etc.) and/or on the progression after revascularization in cases where it is performed.
Secondary Outcomes
- contribution of late 18F-FDG PET metabolic information(12 months)